IGFBP2 is a candidate biomarker for Ink4a- Arf status and a therapeutic target for high-grade gliomas

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 39, 2009, Pages 16675-16679

  Moore, Lynette M ^a   Holmes, Kristen M ^a   Smith, Sarah M ^a   Wu, Ying ^a   Tchougounova, Elena ^b   Uhrbom, Lene ^b   Sawaya, Raymond ^a   Bruner, Janet M ^a   Fuller, Gregory N ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PLATELET DERIVED GROWTH FACTOR B; SOMATOMEDIN BINDING PROTEIN 2;

ARTICLE; CANCER CELL; CONTROLLED STUDY; GENE DELETION; GLIOMA; HISTOPATHOLOGY; MOUSE; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GLIOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-SIS;

MUS MUSCULUS;

EID: 70349731731     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900807106     Document Type: Article

References (31)

1. Collins VP (2007) Mechanisms of disease: Genetic predictors of response to treatment in brain tumors. Nat Clin Prac Oncol 4:362-374. (Pubitemid 46864310)
2. Quon H, Abdulkarim B (2008) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev (2):CD007104. (Pubitemid 351807223)
3. Cairncross JG, et al. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479.
4. Norden AD, Wen PY (2006) Glioma therapy in adults. Neurologist 12:279-292.
5. Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102:37-46. (Pubitemid 38429984)
6. Cunningham D, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345. (Pubitemid 38944402)
7. Rich JN, et al. (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142.
8. Vogelbaum MA, et al. (2009) Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol 11:167-175.
9. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453. (Pubitemid 47339290)
10. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
11. Dunlap SM, et al. (2007) Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104:11736-11741. (Pubitemid 47175082)
12. Fuller GN, et al. (1999) Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: A revelation by parallel gene expression profiling. Cancer Res 59:4228-4232.
13. Sallinen SL, et al. (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60:6617-6622.
14. Mehrian-Shai R, et al. (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/AKT pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 104:5563-5568. (Pubitemid 47175720)
15. Bigner SH, Rasheed BKA, Wiltshire R, McLendon RE (1999) Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncol 1:52-60.
16. Serrano M (2000) The Ink4a/arf locus in murine tumorigenesis. Carcinogenesis 21:865-869.
17. Tchougounova E, et al. (2007) Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene 26:6289-6296. (Pubitemid 47462106)
18. Uhrbom L, et al. (2002) Ink4a-Arf loss cooperates with kras activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated akt. Cancer Res 62:5551-5558.
19. Pao W, Klimstra DS, Fisher GH, Varmus HE (2003) Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Proc Natl Acad Sci USA 100:8764-8769. (Pubitemid 36899173)
20. Baron-Hay S, Boyle F, Ferrier A, Scott C (2004) Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 10:1796-1806. (Pubitemid 38435571)
21. Cohen P, et al. (1993) Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76:1031-1035. (Pubitemid 23110857)
22. Inman BA, et al. (2005) Insulin-like growth factor binding protein 2: An androgen-dependent predictor of prostate cancer survival. Eur Urol 47:695-702. (Pubitemid 40521924)
23. Vorwerk P, et al. (2005) Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab 90:3022-3027. (Pubitemid 40686359)
24. Mendes KN, et al. (2007) Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. J Proteome Res 6:2753-2767.
25. Dai C, et al. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913-1925. (Pubitemid 32738621)
26. Wang H, et al. (2003) Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 63:4315-4321. (Pubitemid 36950996)
27. Arap W, Knudsen ES, Wang JY, Cavenee WK, Huang HJ (1997) Point mutations can inactivate in vitro and in vivo activities of p16(Ink4a)/cdkn2a in human glioma. Oncogene 14:603-609. (Pubitemid 27090963)
28. Sharpless NE (2005) Ink4a/arf: A multifunctional tumor suppressor locus. Mutat Res 576:22-38.
29. Holland EC, Hively WP, DePinho RA, Varmus HE (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12:3675-3685.
30. Serrano M, et al. (1996) Role of the ink4a locus in tumor suppression and cell mortality. Cell 85:27-37. (Pubitemid 26116804)
31. Jabbur JR, et al. (2002) Mdm-2 binding and taf(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues thr18 and asp21. Oncogene 21:7100-7113.